Cargando...
Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer
INTRODUCTION: Erlotinib and gefitinib are the most commonly used epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of EGFR mutant nonsmall cell lung cancer (NSCLC). Both erlotinib and gefitinib have shown equal efficacy in terms of response rates and overall su...
Gardado en:
| Publicado en: | Indian J Med Paediatr Oncol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5398099/ https://ncbi.nlm.nih.gov/pubmed/28469331 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0971-5851.203502 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|